<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934687</url>
  </required_header>
  <id_info>
    <org_study_id>2009DR2125</org_study_id>
    <secondary_id>EKBB14/09</secondary_id>
    <nct_id>NCT00934687</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for the Treatment of Depression</brief_title>
  <official_title>Clostridium Botulinum Type A Neurotoxin Complex for Adjuvant Treatment of Depressive Disorders - a Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is frequently accompanied by a specific sad facial expression. This expression is
      in part mediated by the same muscle activity that produces frown lines. Based on the
      assumption that there is a positive feedback between depressed mood and the correspondent
      facial muscle activity (facial feedback) the investigators will conduct a randomized
      controlled pilot study in which the investigators will apply a classical cosmetic treatment
      of frown lines with injections of botulinum toxin to depressed patients who did not
      sufficiently respond to antidepressant medication. The investigators hypothesize that this
      treatment will contribute to the amelioration of depressive symptoms in these patients. This
      hypothesis is supported by a previous open case series in which remission of depression was
      reported after such treatment (Finzi and Wasserman, 2006).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (reduction in Ham-D score by &gt;30% compared to baseline)</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate (number of patients with HAM-D score &lt; 8)</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (20% reduction of HAM-D score compared to baseline)</measure>
    <time_frame>two, four, or six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response by self rating (BDI)</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for additional treatment</measure>
    <time_frame>eight weeks, twelve weeks, or sixteen weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>clostridium botulinum toxin type A neurotoxin complex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% sodium chloride NaCl solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl solution will be injected like the experimental compound</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clostridium botulinum toxin type A neurotoxin complex</intervention_name>
    <description>A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.</description>
    <arm_group_label>clostridium botulinum toxin type A neurotoxin complex</arm_group_label>
    <other_name>Vistabel</other_name>
    <other_name>Botox Cosmetic</other_name>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% NaCl solution</intervention_name>
    <description>0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.</description>
    <arm_group_label>0.9% sodium chloride NaCl solution</arm_group_label>
    <other_name>NaCl 0.9% B. Braun</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate depression (Ham-D &gt;=15)

          -  Therapy with one antidepressant for at least four weeks

          -  at least moderate frown line

        Exclusion Criteria:

          -  Bipolar depression

          -  Psychiatric comorbidity

          -  Severe somatic comorbidity

          -  Pregnancy

          -  Peculiarities at the injection site

          -  Psychiatric medication other than one antidepressant

          -  Specific psychotherapy

          -  Previous application of botulinum toxin

          -  Medication interfering with botulinum toxin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc A Wollmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik Nord - Ochsenzoll, Hamburg/D</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tillmann HC Kr√ºger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical School HannoverPsychiatry, Social Psychiatry and Psychotherapy, Hannover, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical School Hannover, Psychiatry, Social Psychiatry and Psychotherapy</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatry Hospital of the University of Basel, Basel, Switzerland</name>
      <address>
        <city>Basel</city>
        <state>Basel Town</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>depressive</keyword>
  <keyword>botulinum</keyword>
  <keyword>botox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

